Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $9.09 and traded as low as $8.42. Arcturus Therapeutics shares last traded at $8.44, with a volume of 430,117 shares.
Analysts Set New Price Targets
Several research firms have recently issued reports on ARCT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Wall Street Zen raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Zacks Research upgraded shares of Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Roth Capital reiterated a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. Finally, Citigroup raised shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $8.00 to $20.00 in a report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $24.50.
Check Out Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
The firm’s 50 day simple moving average is $12.57 and its 200-day simple moving average is $9.09. The company has a market cap of $243.24 million, a price-to-earnings ratio of -2.74 and a beta of 2.62.
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.43. Arcturus Therapeutics had a negative return on equity of 46.79% and a negative net margin of 285.92%. The business had revenue of $18.30 million for the quarter, compared to analysts’ expectations of $8.00 million. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.96 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its position in Arcturus Therapeutics by 648.6% during the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock worth $42,000 after buying an additional 2,627 shares during the period. Ground Swell Capital LLC purchased a new stake in Arcturus Therapeutics in the third quarter valued at approximately $140,000. Two Sigma Securities LLC purchased a new stake in Arcturus Therapeutics in the second quarter valued at approximately $80,000. ADAR1 Capital Management LLC acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $116,000. Finally, Diversify Wealth Management LLC acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $133,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.
Read More
- Five stocks we like better than Arcturus Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
